We are a fully-integrated, biopharmaceutical company focused on the discovery, development and commercialization of transformative and well-tolerated targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases.

Corporate information

Board of Directors

Carrie Cox

Chairman, Array BioPharma Inc. Board of Directors; and Former Chairman and Chief Executive Officer of Humacyte, Inc.

Audit Committee
Corporate Governance Committee

Charles Baum, M.D., Ph.D.

President and Chief Executive Officer, Mirati Therapeutics, Inc.

Corporate Governance
Clinical Development Committee

Gwen Fyfe, M.D.

Independent Consultant and Former Vice President, Oncology Development, Genentech, Inc.

Corporate Governance Committee
Clinical Development Committee

Kyle Lefkoff

General Partner, Boulder Ventures Ltd.

Audit Committee
Compensation Committee

John Orwin

President and Chief Executive Officer, Atreca, Inc.

Compensation Committee
Clinical Development Committee

Shalini Sharp

Chief Financial Officer and Executive Vice President, Ultragenyx Pharmaceutical Inc.

Audit Committee
Compensation Committee

Ron Squarer

Chief Executive Officer, Array BioPharma Inc.

Gil Van Lunsen

Former Managing Partner, KPMG LLP

Audit Committee
Corporate Governance Committee

Executive Officers

Ron Squarer

Chief Executive Officer

Jason Haddock

Chief Financial Officer

Curtis Oltmans

Executive Vice President,
General Counsel and Secretary

Andrew Robbins

Chief Operating Officer

Nicholas Saccomano, Ph.D.

Chief Scientific Officer

Victor Sandor, M.D.

Chief Medical Officer

Stakeholder Information

Outside Legal Counsel

Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Washington, DC

Independent Auditors

Denver, CO

Transfer Agent and Registrar

Communications concerning stock transfer requirements, lost certificates and changes of address should be directed to the Transfer Agent:
American Stock Transfer and Trust Company
6201 15th Avenue
Brooklyn, NY 11219

Annual Meeting

October 25, 2018
1:00 pm MDT
1825 33rd Street
Boulder, CO 80301

Corporate Headquarters

Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301

Stockholder Inquiries

Inquiries from stockholders and potential investors regarding our company are always welcome and will receive a prompt response. Please direct your requests for information to:
Investor Relations
Array BioPharma Inc.
3200 Walnut Street
Boulder, CO 80301
Information regarding Array BioPharma is also available at: www.arraybiopharma.com

Stock Listing

Array BioPharma common stock is traded on the Nasdaq Stock Market under the symbol ARRY.


This Annual Report and other documents we file with the Securities and Exchange Commission, or SEC, contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties. In addition, we may make forward-looking statements in our press releases or in other oral or written communications with the public. These forward-looking statements include, among others, statements about the future development plans of encorafenib and binimetinib; expectations that events will occur that will create greater value for Array; and the potential for the results of current and future clinical trials to support regulatory approval or the marketing success of encorafenib and binimetinib. Because these statements reflect our current expectations concerning future events and involve significant risks and uncertainties, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, the potential that the FDA, EMA or other regulatory agencies determine results from clinical trials are not sufficient to support registration or marketing approval of encorafenib and binimetinib; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials and to manufacture drug substance and product within and outside the United States (U.S.); our ability to grow and successfully develop commercialization capabilities; our ability to achieve and maintain profitability and maintain sufficient cash resources; and our ability to attract and retain experienced scientists and management. Additional information concerning these and other risk factors can be found in the Annual Report on Form 10-K, under the caption "Item 1A. Risk Factors." We are providing this information as of the date of this report. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.


Unless otherwise indicated, information contained in the Annual Report on Form 10‑K concerning the cancer market, the drug market and our other markets, including our general expectations and market position, market opportunity and market share, is based on information from independent industry analysts and third-party sources and management estimates. Management estimates are derived from publicly available information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on assumptions made by us based on such data and our knowledge of such industry and markets, which we believe to be reasonable.

We have not independently verified or verified with any independent source any third-party information. In addition, while we believe the market position, market opportunity and market share information included in the Annual Report on Form 10-K is generally reliable, such information is inherently imprecise. Such data involves risks and uncertainties and is subject to change based on various factors, including those discussed under the heading "Item 1A. Risk Factors."